The CBD .fr team has translated the MARIJUANA DAILY BUSINESS article into French for your convenience… you will find the origin of this article written by .
Argentine authorities have issued a new decree aimed at addressing the shortcomings in the rules governing the medical cannabis sector in the country, which has largely failed to materialize since an initial law and decree were approved in 2017.
The new decree replaces the 2017 version, which did not facilitate significant access to medical cannabis and, by extension, opportunities for businesses.
The new decree allows pharmacies to dispense compounded cannabis preparations.
It broadens the scope of the law by allowing, in principle, access to medical cannabis for any medical condition – not just refractory epilepsy, as was the case with the 2017 version of the regulation.
One of the objectives of the new decree is to facilitate subsidized access to cannabis derivatives for patients with a "medical indication".
The updated decree includes a series of objectives that somewhat overlap with those of the 2017 version, including research-focused objectives.
The decree acknowledges that "regulatory restrictions" have prevented access to medical cannabis.
In its introduction, the new decree notes that the rules have hitherto only allowed people with refractory epilepsy to effectively access cannabis products, but the products have been out of reach for most patients due to the high cost of importing them.
The 2017 law and decree also listed an objective to provide free medical cannabis to patients in the program.
This has simply never happened in any significant way.
The 2020 decree will allow individuals to register to grow marijuana at home for medical purposes, a move that has been welcomed by patients and activists.
This could potentially lead to ancillary business opportunities for entrepreneurs targeting the niche home growing market – like their counterparts in Canada.
Roberto Padilla, a local regulatory advisor, sees the news as "a victory for pro-cannabis activists who are now finding a government more receptive to decriminalization proposals.".
Patients with a "medical indication" will be able to enroll in the government program to raise their child at home or have a third party or association raise their child for them.
However, registration requirements and other details, such as patient growth capacity, remain unknown.
Further secondary regulations will need to be drafted in the future.
Also read:
Editor-in-Chief specializing in CBD
Julien, born on July 17, 1978, in the Paris region, is a prominent writer and expert in the field of CBD products. Following his studies, Julien developed a passion for natural remedies, including CBD. In 2022, he joined the CBD.fr team as an expert and regular contributor. Thanks to his scientific expertise and clear writing style, Julien helps demystify the complexities of CBD, while highlighting its benefits and potential applications through his articles and conference presentations.
